Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy
JAMA · 20.02.2024 · 331 (7) · 573
DOI: 10.1001/jama.2023.27188 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 20.02.2024. Verfasst von Hooman Kamel und 30 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Translational Neuroscience Unit, Department of Neurology and Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New …. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke, Heart Diseases, Ischemic Stroke. Die Arbeit wurde bisher 223-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS.
Themen: Schlaganfall
Abstract (Originalsprache)
Importance Atrial cardiopathy is associated with stroke in the absence of clinically apparent atrial fibrillation. It is unknown whether anticoagulation, which has proven benefit in atrial fibrillation, prevents stroke in patients with atrial cardiopathy and no atrial fibrillation.
Objective
To compare anticoagulation vs antiplatelet therapy for secondary stroke prevention in patients with cryptogenic stroke and evidence of atrial cardiopathy. Design, Setting, and Participants Multicenter, double-blind, phase 3 randomized clinical trial of 1015 participants with cryptogenic stroke and evidence of atrial cardiopathy, defined as P-wave terminal force greater than 5000 μV × ms in electrocardiogram lead V 1 , serum N-terminal pro-B-type natriuretic peptide level greater than 250 pg/mL, or left atrial diameter index of 3 cm/m 2 or greater on echocardiogram. Participants had no evidence of atrial fibrillation at the time of randomization. Enrollment and follow-up occurred from February 1, 2018, through February 28, 2023, at 185 sites in the National Institutes of Health StrokeNet and the Canadian Stroke Consortium.
Interventions
Apixaban, 5 mg or 2.5 mg, twice daily (n = 507) vs aspirin, 81 mg, once daily (n = 508). Main Outcomes and Measures The primary efficacy outcome in a time-to-event analysis was recurrent stroke. All participants, including those diagnosed with atrial fibrillation after randomization, were analyzed according to the groups to which they were randomized. The primary safety outcomes were symptomatic intracranial hemorrhage and other major hemorrhage.
Results
With 1015 of the target 1100 participants enrolled and mean follow-up of 1.8 years, the trial was stopped for futility after a planned interim analysis. The mean (SD) age of participants was 68.0 (11.0) years, 54.3% were female, and 87.5% completed the full duration of follow-up. Recurrent stroke occurred in 40 patients in the apixaban group (annualized rate, 4.4%) and 40 patients in the aspirin group (annualized rate, 4.4%) (hazard ratio, 1.00 [95% CI, 0.64-1.55]). Symptomatic intracranial hemorrhage occurred in 0 patients taking apixaban and 7 patients taking aspirin (annualized rate, 1.1%). Other major hemorrhages occurred in 5 patients taking apixaban (annualized rate, 0.7%) and 5 patients taking aspirin (annualized rate, 0.8%) (hazard ratio, 1.02 [95% CI, 0.29-3.52]). Conclusions and Relevance In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not significantly reduce recurrent stroke risk compared with aspirin. Trial Registration ClinicalTrials.gov Identifier: NCT03192215
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical and Translational Neuroscience Unit, Department of Neurology and Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, New York.
- Department of Neurology, University of Washington, Seattle.
- Department of Medicine, University of Washington, Seattle.
- Department of Epidemiology, University of Washington, Seattle.
- Department of Biostatistics, University of Washington, Seattle.
- Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.
Förderung
- NINDS NIH HHS
Zitieren
APA
Kamel, H., Longstreth, W. T., Tirschwell, D. L., Kronmal, R. A., Marshall, R. S., Broderick, J. P., Aragón García, R., Plummer, P., Sabagha, N., Pauls, Q., Cassarly, C., Dillon, C. R., Di Tullio, M. R., Hod, E. A., Soliman, E. Z., Gladstone, D. J., Healey, J. S., Sharma, M., Chaturvedi, S., …, & ARCADIA Investigators (2024). Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy. JAMA, 331(7), 573. https://doi.org/10.1001/jama.2023.27188
Vancouver
Kamel H, Longstreth WT, Tirschwell DL, Kronmal RA, Marshall RS, Broderick JP, et al. Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy. JAMA. 2024;331(7):573. doi:10.1001/jama.2023.27188
BibTeX
@article{Kamel2024,
author = {Kamel, Hooman and Longstreth, W T and Tirschwell, David L and Kronmal, Richard A and Marshall, Randolph S and Broderick, Joseph P and Aragón García, Rebeca and Plummer, Pamela and Sabagha, Noor and Pauls, Qi and Cassarly, Christy and Dillon, Catherine R and Di Tullio, Marco R and Hod, Eldad A and Soliman, Elsayed Z and Gladstone, David J and Healey, Jeff S and Sharma, Mukul and Chaturvedi, Seemant and Janis, L Scott and Krishnaiah, Balaji and Nahab, Fadi and Kasner, Scott E and Stanton, Robert J and Kleindorfer, Dawn O and Starr, Matthew and Winder, Toni R and Clark, Wayne M and Miller, Benjamin R and Elkind, Mitchell S V and ARCADIA Investigators, ARCADIA Investigators},
title = {Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy},
journal = {JAMA},
year = {2024},
volume = {331},
number = {7},
pages = {573},
doi = {10.1001/jama.2023.27188}
}
EUVIMED